Traditionally used for anxiety; social anxiety; anxiety without cognitive impairment.
Traditional uses
- For anxiety—one of the most effective herbal anxiolytics
- For social anxiety
- For anxiety without cognitive impairment (traditionally used before important meetings)
- For muscle tension with anxiety
Conditions it is used for
Nervous System & Mental State
In the old texts
Kava has been central to Pacific Island cultures for over 3,000 years—used ceremonially, socially, and medicinally. The root is prepared as a beverage that produces relaxation and mild euphoria without impairing mental clarity. It gained attention in Western herbalism for anxiety and has been extensively studied.
What does the work
- Kavalactones
- Lipophilic lactones from kava root (Piper methysticum), including kavain, dihydrokavain, methysticin, and yangonin.
Cautions
- Drug interactions Serious
Herbs can alter drug metabolism via CYP450 induction (St. John’s wort induces CYP3A4 1) or inhibition (piperine inhibits CYP3A4 and P-glycoprotein), causing subtherapeutic or toxic drug levels. - Liver conditions Serious
Hepatotoxic constituents including pyrrolizidine alkaloids, pulegone (pennyroyal), and kava lactones can cause veno-occlusive disease, centrilobular necrosis, or cholestatic injury in susceptible individuals 2. - Sedation Worth knowing
GABAergic herbs (valerian, kava, passionflower) potentiate GABA-A receptor activity, producing additive sedation when combined with benzodiazepines, barbiturates, or alcohol 3.
These are the cautions recorded for this plant, not a complete list. Doses, preparations and interactions vary; ask a pharmacist or qualified practitioner before combining a herb with medication.
Research references
- Moore LB et al.. St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA, 2000.
- Teschke R et al.. Herbal hepatotoxicity: a tabular compilation of reported cases. Liver Int, 2012.
- Khom S et al.. Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificity. Neuropharmacology, 2007.